SML2829

SB-204990

≥98% (HPLC), ATP citrate-lyase inhibitor, powder

• Sinónimos: (+/-) (3R*,5S*)-rel-5-[6-(2,4-Dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid, SB 201076 prodrug, SB 204990, SB-201076 prodrug, SB201076 prodrug, SB204990
• Fórmula empírica (notación de Hill): C₁₈H₂₂Cl₂O₅
• Número CAS: 154566-12-8
• Peso molecular: 389.27
• UNSPSC Code: 51111800
• NACRES: NA.77
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Nombre del producto: SB-204990, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: 2-8°C
• SMILES string: Clc1c(ccc(c1)Cl)CCCCCC[C@H]2OC(=O)[C@@](C2)(O)CC(=O)O
• InChI: 1S/C18H22Cl2O5/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14-10-18(24,11-16(21)22)17(23)25-14/h7-9,14,24H,1-6,10-11H2,(H,21,22)/t14-,18+/m1/s1
• InChI key: YTRNLFYTHYWDAU-KDOFPFPSSA-N

Descripción

Biochem/physiol Actions

ATP citrate-lyase inhibitor SB-201076 γ-lactone prodrug with cell-permeability, oral availability and in vivo hypocholesterolaemic/hypolipidaemic efficacy.

SB-204990 is a cell-permeable and orally available γ-lactone prodrug of the non-cell-permeable SB-201076 that inhibits human and rat ATP citrate-lyase (K_i =1 μM against human and rat ACL) in a predominantly competitive manner with a small but significant uncompetitive component. SB-204990 treatment is shown to suppress the rate of cellular cholesterol and fatty acid synthesis in HepG2 cultures (by 91% & 82%, respectively, with 30 μM SB-204990), and display hypocholesterolaemic and hypolipidaemic efficacy in vivo when administered in the diet (0.05-0.25%, w/w; mice, rats, dogs).

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• ¿Qué está pasando?: WGK 3
• Punto de inflamación (°F): Not applicable
• Punto de inflamación (°C): Not applicable